Imlunestrant

Memorial Sloan Kettering Cancer Center (MSK) made significant strides in cancer treatment in 2024, including novel vaccines, drugs enhancing radiation, and advanced diagnostics.

Imlunestrant monotherapy significantly improved progression-free survival (PFS) in advanced breast cancer patients with ESR1 mutations compared to standard endocrine therapy.

Eli Lilly's Imlunestrant, an oral selective estrogen receptor degrader (SERD), will have its Phase 3 EMBER-3 trial results presented at the San Antonio Breast Cancer Symposium (SABCS).

Imlunestrant, a next-generation oral selective estrogen receptor degrader, demonstrates a manageable safety profile and preliminary antitumor activity in advanced breast cancer.

The EMBER3 trial suggests combining imlunestrant with abemaciclib could be more effective than imlunestrant alone for advanced ER-positive, HER2-negative breast cancer.